<bill session="115" type="s" number="3420" updated="2023-01-11T13:41:22Z">
  <state datetime="2018-09-06">REFERRED</state>
  <status>
    <introduced datetime="2018-09-06"/>
  </status>
  <introduced datetime="2018-09-06"/>
  <titles>
    <title type="display">Accountability in Opioid Advertising Act</title>
    <title type="official" as="introduced">A bill to require the Food and Drug Administration to prioritize the promotional materials for drugs for serious, life-threatening diseases or conditions or substance use disorders, especially opioid drugs and drugs for medication-assisted treatment, in considering whether promotional materials are false or misleading.</title>
    <title type="short" as="introduced">Accountability in Opioid Advertising Act</title>
  </titles>
  <sponsor bioguide_id="H001075"/>
  <cosponsors>
    <cosponsor bioguide_id="G000562" joined="2018-09-06"/>
  </cosponsors>
  <actions>
    <action datetime="2018-09-06">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2018-09-06" state="REFERRED">
      <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
    </action>
  </actions>
  <committees>
    <committee code="SSHR" name="Senate Health, Education, Labor, and Pensions" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Civil actions and liability"/>
    <term name="Consumer affairs"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Drug therapy"/>
    <term name="Drug trafficking and controlled substances"/>
    <term name="Drug, alcohol, tobacco use"/>
    <term name="Fraud offenses and financial crimes"/>
    <term name="Marketing and advertising"/>
    <term name="Prescription drugs"/>
    <term name="Television and film"/>
  </subjects>
  <amendments/>
  <summary date="2019-08-20T20:30:37Z" status="Introduced in Senate">Accountability in Opioid Advertising Act

This bill requires the Food and Drug Administration to prioritize the review of advertising and other promotional materials for drug for serious, life-threatening diseases or conditions or substance use disorders, especially opioids (drugs with effects similar to opium, such as certain pain medications)and drugs used in the treatment of opioid use disorders.</summary>
</bill>
